Ali Al-Ameri, MD

Ali Al-Ameri, MD, completed his medical degree in 1985 at Baghdad College of Medicine in Iraq. After relocating to the United States, Dr. Al-Ameri completed an Internal Medicine residency at Akron General Medical Center in Ohio and was a clinical leukemia fellow at The University of Texas MD Anderson Cancer Center in Houston, Texas. He joined Kelsey-Seybold’s Internal Medicine department in March 2024.

As an internist, Dr. Al-Ameri provides primary care for adult patients. In addition to providing well checks, physicals, and immunizations, he diagnoses and treats a broad range of symptoms and conditions, including hypertension, diabetes, obesity, respiratory infections, joint pain, arthritis, stomach distress, and more.

Awards

• IIE Scholar Rescue Fund (SRF) Award, 2008
• IIE Scholar Rescue Fund (SRF) Award, 2007
• International Novo Nordisk Hemophilia Foundation, 2006
• Letter of Recognition from the Minister of Higher Education Iraq, 2005
• Letter of Recognition from Dean of Al-Mustansiryia University, 2005
• Letter of Recognition from Dean of Al-Mustansiryia University, 2004
• Letter of Recognition from the Minister of Health, Iraq, 2002
• Letter of Recognition from the Minister of Higher Education, Iraq, 2001
• Letter of Recognition from Dean of Al-Mustansiryia Medical Schoo1, 1998 – 1999
• Nominated by residents for Teaching Award, 1994 – 2006
• Letter of Recognition from chair of the Department of Internal Medicine Baghdad Medical City, 1990
• Letter of Recognition from the General Director of Al-Najaf Governorate section of health, 1986

Publications

Peer review

• De Yao JT, Al-Ameri A, Garcia-Manero G, Quintás-Cardama A. Infrequent presentations of mucormycosis in patients with myelodysplastic syndrome and acute leukemia: case series and review of literature. Clin Lymphoma Myeloma Leuk. 2011 Oct;11(5):446-51.
• Al-Ameri A, Cherry M, Garcia-Manero G, Quintás-Cardama A. Standard therapy for patients with myelodysplastic syndromes. Clin Lymphoma Myeloma Leuk. 2011 Aug;11(4):303-13.
• Al Ameri A, Jabbour E, Garcia-Manero G, O'Brien S, Faderl S, Ravandi F, Shan J, Pierce S, Cortes J, Kantarjian H. Significance of thrombocytopenia in myelodysplastic syndromes: associations and prognostic implications. Clin Lymphoma Myeloma Leuk. 2011 Apr;11(2):237-41.
• Al Ameri A, Koller C, Kantarjian H, Ravandi F, Verstovsek S, Borthakur G, Pierce S, Mattiuzzi G. Acute pulmonary failure during remission induction chemotherapy in adults with acute myeloid leukemia or high-risk myelodysplastic syndrome. Cancer. 2010 Jan 1;116(1):93-7.
• Al Ameri A. Baker NS. Successful use of activated recombinant factor VII in the treatment of vitreous hemorrhage. Report of Seven Cases. Blood Coagulation & Fibrinolysis 2005 Nov; 16(ISSN 0957-5235): 573-8

Online Publication:

• Ali Al-Ameri, Mohamad Cherry, Aref Al-Kali,Alessandra Ferrajoli. The Role of Monoclonal Antibodies in the Management of Leukemia. Pharmaceuticals 2010, 3, 3258-3274

Abstracts and Poster Presentations:

• Ali Al-Ameri, Mohamed Abdelfatah , Zeyad Kanaan, Nairmeen Haller. Outcome of Acute Myeloid Leukemia AML &High Risk MDS Treated According to the Standard of Care in Community Hospital, Data from Single Center (2001–2010). Blood (ASH Annual Meeting Abstracts) 2012 120: (Abstract).
• Ali Al-Ameri, Neema Patel, Zeyad Kanaan, Nairmeen Haller. Management of acute myeloid leukemia (AML) and high-risk myelodysplastic syndrome (MDS) in community services: Retrospective study of 130 patients from a single institution. 2012 ASCO Annual Meeting (Abstract).
• Ali Al-Ameri, Deborah A. Thomas, Farhad Ravandi, Susan O’Brien, Hagop M. Kantarjian, Gautam Borthakur, Tapan Kadia, Mary Kelly, Rebecca Garris, Stefan Faderl Phase II study of Hyper-CVAD followed by Nelarabine Consolidation in Newly Diagnosed Patients with T Cell, ASCO 2011( poster )
• A Al-Kali, H Kantarjian, C Bueso-Ramos, S Konoplev, A Al-Ameri, S Pierce, M Brandt, E Jabbour, A Quintas-Cardama, S O’Brien, J Cortes. Cuplike Nuclei in Acute Myeloid leukemia: A Specific Entity with Increased FLT3 ITD and NPM1 Mutation, EHA 2010 (poster)
• Ali Al-Ameri, Jorge Cortes, Hagop Kantarjian, Elizabeth Burton, Alfonso Quintas-Cardama, Elias. Infectious Events in Patients with Chronic Myeloid Leukemia Treated Nilotinib as a Front Line therapy and after Imatinib Failure. ASH 2010 (poster).
• Ali Al-Ameri, Srdan Verstovsek, Hagop Kantarjian, Gautam Borthakur. Decitabine and Gemtuzumab Ozogamicin In patients with advanced Myelofibrosis. ASH 2010. (Abstract).
• Ali Al-Ameri, Xavier Badoux, Alessandra Ferrajoli, William Wierda, Luis Fayad, Zeev Estrov, Susan Bickel, Michael Keating and Susan O’Brien.. Phase II Study of Dasatinib in Patients with Relapsed Chronic Lymphocytic Leukemia. ASH 2010. (Abstract).
• Baljevic, M , Kantarjian H, Al Ameri, A , Pierce, S, Cortes J. Megakaryocytic Blastic Phase (BP) of Chronic Myeloid Leukemia (CML) A Single Institution Experience. EHA 2010. (Poster).
• Xavier Badoux, Ali M Al-Ameri, Susan O'Brien, William G. Wierda, Jan A. Burger, Stefan Faderl, Zeev Estrov, Susan Lerner, MS, Michael J Keating, Alessandra Ferrajoli. Retrospective Analysis of the Experience with Rituximab and Methyl prednisone In Elderly Patients with CLL. ASH 2010. (Abstract).
• Baljevic, M, Kantarjian H, Al- Ameri, A, Pierce, S, Cortes J. Megakaryocytic Blastic Phase (BP) of Chronic Myeloid Leukemia (CML) –A Single Institution Experience. EHA 2010 (Poster).
• A Al-Kali, H Kantarjian, C Bueso-Ramos, S Konoplev, A Al-Ameri, S Pierce, M Brandt, E Jabbour, A Quintas-Cardama, S O’Brien, J Cortes.Cuplike Nuclei in Acute Myeloid leukemia: A Specific Entity with Increased FLT3 ITD and NPM1 Mutation. EHA 2010 (Abstract).
• Ali Al Ameri, Hagop Kantarjian, Susan O’Brien, Farhad Ravandi, Gautam Borthakur, Brenda Walker, Elizabeth Burton, Mary Beth Rios, Jorge Cortes. Low Risk of Infectious Events in Patients (Pts) with Chronic Myeloid Leukemia (CML) in Chronic Phase (CP) Treated with Dasatinib. ASH 2009 (Poster).
• Ali Al-Ameri, Hagop Kantarjian, Gautam Borthakur, Erkut Bahceci.Ted Szatrowski, Andrew Damokosh, and Jorge Cortes Opportunistic Infections Are Uncommon with Dasatinib in Patients with Chronic Myeloid Leukemia In Chronic Phase (CML-CP). ASH 2009 (Poster).
• Al-Ameri Ali, Alkuhder M, Batool, k. Al-Mudahfer, A. Murad, N. Epidemiology of chronic myeloid leukemia in Iraqi patients. EHA Conference Berlin 2009 (Abstract).
• Al-Ameri A, Koller C, Mathuzzi, G. Pulmonary Hemorrhage in AML and High-risk MDS ASH 2008 (Abstract).